#alteogen — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #alteogen, aggregated by home.social.
-
Alteogen secures MFDS approval for Eylea biosimilar Eyzen-F Inj, entering South Korea's aflibercept market following European approval, with Phase 3 trials demonstrating therapeutic equivalence and safety across 12 countries
#YonhapInfomax #Alteogen #EyleaBiosimilar #EyzenFInj #MFDSApproval #Aflibercept #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=120657 -
Alteogen secures MFDS approval for Eylea biosimilar Eyzen-F Inj, entering South Korea's aflibercept market following European approval, with Phase 3 trials demonstrating therapeutic equivalence and safety across 12 countries
#YonhapInfomax #Alteogen #EyleaBiosimilar #EyzenFInj #MFDSApproval #Aflibercept #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=120657 -
Alteogen secures MFDS approval for Eylea biosimilar Eyzen-F Inj, entering South Korea's aflibercept market following European approval, with Phase 3 trials demonstrating therapeutic equivalence and safety across 12 countries
#YonhapInfomax #Alteogen #EyleaBiosimilar #EyzenFInj #MFDSApproval #Aflibercept #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=120657 -
Alteogen secures MFDS approval for Eylea biosimilar Eyzen-F Inj, entering South Korea's aflibercept market following European approval, with Phase 3 trials demonstrating therapeutic equivalence and safety across 12 countries
#YonhapInfomax #Alteogen #EyleaBiosimilar #EyzenFInj #MFDSApproval #Aflibercept #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=120657 -
Global pharmaceutical firms are paying upfront to secure technology transfer deals with Alteogen, as demand for its subcutaneous injection platform surges; Shinhan Investment maintains a 730,000 won target price, citing strong licensing prospects despite recent patent litigation.
#YonhapInfomax #Alteogen #TechnologyTransfer #ShinhanInvestment #OptionAgreement #TargetPrice730000Won #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=97468 -
Global pharmaceutical firms are paying upfront to secure technology transfer deals with Alteogen, as demand for its subcutaneous injection platform surges; Shinhan Investment maintains a 730,000 won target price, citing strong licensing prospects despite recent patent litigation.
#YonhapInfomax #Alteogen #TechnologyTransfer #ShinhanInvestment #OptionAgreement #TargetPrice730000Won #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=97468 -
Global pharmaceutical firms are paying upfront to secure technology transfer deals with Alteogen, as demand for its subcutaneous injection platform surges; Shinhan Investment maintains a 730,000 won target price, citing strong licensing prospects despite recent patent litigation.
#YonhapInfomax #Alteogen #TechnologyTransfer #ShinhanInvestment #OptionAgreement #TargetPrice730000Won #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=97468 -
Global pharmaceutical firms are paying upfront to secure technology transfer deals with Alteogen, as demand for its subcutaneous injection platform surges; Shinhan Investment maintains a 730,000 won target price, citing strong licensing prospects despite recent patent litigation.
#YonhapInfomax #Alteogen #TechnologyTransfer #ShinhanInvestment #OptionAgreement #TargetPrice730000Won #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=97468